New Diagnostic Test "Epinex” Provides Thirty Day Average Blood Glucose

The Epinex G1A™ Rapid Diabetes Monitoring Index Test is a new monthly rapid test that uses glycated albumin to measure how much damage has been done to the body by excess sugar. 

This test could allow doctors to take action sooner than current diabetes testing methods, reducing the severity and cost of diabetes and its complications, which include blindness, kidney failure and cardiac disease.

Diabetes eats up an enormous chunk of our current healthcare resources.  It has become the greatest healthcare crisis of our time, affecting one in three Americans.  Last year alone, direct medical costs for diabetes totaled $116 billion, a 32% increase since 2002.  Despite current efforts to manage the epidemic, the toll of diabetes continues to spiral out of control.  However, pouring more resources into ineffective programs will only waste money.

Continuing to address the diabetes epidemic using methods of the past threatens to set up our health care system for failure.  "The current treatment paradigm for diabetes doesn't work," explains Epinex CEO, Asad Zaidi.  "With our current financial crisis, Epinex is working on a product that will help save our already over-burdened healthcare system billions of dollars, while helping diabetics manage their disease more effectively."

Epinex Diagnostics is a privately owned medical device company with a vision to help alleviate the current healthcare crisis through the development of innovative point-of-care technologies using rapid diagnostic tests.  Please find further information about the company and the G1A™ test at www.epinex.com.